In the last trading session, 1.19 million shares of the Autolus Therapeutics plc ADR (NASDAQ:AUTL) were traded, and its beta was 2.04. Most recently the company’s share price was $1.92, and it changed around -$0.11 or -5.42% from the last close, which brings the market valuation of the company to $510.95M. AUTL currently trades at a discount to its 52-week high of $7.37, offering almost -283.85% off that amount. The share price’s 52-week low was $1.99, which indicates that the current value has fallen by an impressive -3.65% since then. We note from Autolus Therapeutics plc ADR’s average daily trading volume that its 10-day average is 1.15 million shares, with the 3-month average coming to 1.70 million.
Autolus Therapeutics plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended AUTL as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Autolus Therapeutics plc ADR is expected to report earnings per share of -0.24 for the current quarter.
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Instantly AUTL has showed a red trend with a performance of -5.42% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.23 on recent trading dayincreased the stock’s daily price by 13.9%. The company’s shares are currently down -18.30% year-to-date, but still down -9.00% over the last five days. On the other hand, Autolus Therapeutics plc ADR (NASDAQ:AUTL) is -20.33% down in the 30-day period. We can see from the shorts that 8.38 million shares have been sold at a short interest cover period of 5.64 day(s).
The consensus price target as assigned by Wall Street analysts is $7.6, which translates to bulls needing to increase their stock price by 74.74% from its current value. Analyst projections state that AUTL is forecast to be at a low of $7.6 and a high of $7.6.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
The year-over-year growth rate is expected to be 920.38%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 2.98M in revenue for the current quarter. Forecasts for the next quarter put sales growth at -100.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 3.32%. Autolus Therapeutics plc ADR earnings are expected to increase by 24.89% in 2025, but the outlook is positive 21.23% per year for the next five years.
AUTL Dividends
Autolus Therapeutics plc ADR’s next quarterly earnings report is expected to be released in March.
BLACKSTONE INC., with 9.2207% or 20.49 million shares worth $71.29 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
